Skip to content
Open access

Analytical Performance of Routine Next-Generation Sequencing in Biopsy and Resection Specimens from Patients with Colorectal Adenocarcinoma: A Two-Center Study

Sep 2026 · OSMANGAZİ JOURNAL OF MEDICINE · 0 citations · 17 references

TL;DR

Despite lower tumor cellularity and DNA concentration, appropriately selected biopsy specimens yielded high rates of evaluable sequencing and Tier I–II variant detection in this cohort, with no statistically significant differences in sequencing quality metrics or Tier I–II variant yield between specimen types.

Abstract

Biopsy specimens are increasingly used for molecular profiling in colorectal cancer, although their limited tissue volume and lower DNA yield may present preanalytical challenges. This retrospective, two-center study compared DNA-based analytical performance between 34 resection and 31 biopsy specimens from patients with colorectal adenocarcinoma. Tumor percentage, DNA concentration, sequencing coverage, the proportion of target bases covered at ≥500×, and Tier I–II variant yield were evaluated. Biopsy specimens had lower median tumor percentages (50% vs. 70%; p=0.016) and DNA concentrations (21.35 vs. 55.20 ng/µL; p<0.001) than resection specimens. An evaluable DNA-based NGS result was obtained in 30 of 31 biopsy specimens and all 34 resection specimens, with no statistically significant difference between the groups (96.8% vs. 100%; p=0.477). No significant differences were observed in median sequencing coverage (1149.0× vs. 1084.5×; p=0.586), the proportion of target bases covered at ≥500× (93.87% vs. 91.37%; p=0.752), or detection of at least one Tier I–II variant (100% vs. 94.1%; p=0.494). Variant counts, numbers of altered genes, and variant allele frequency measures did not differ significantly between biopsy and resection specimens. After adjustment for tumor percentage and block age, biopsy specimens remained independently associated with lower DNA concentration, with an adjusted geometric mean ratio of 0.45 (95% CI: 0.30–0.68). Despite lower tumor cellularity and DNA concentration, appropriately selected biopsy specimens yielded high rates of evaluable sequencing and Tier I–II variant detection in this cohort, with no statistically significant differences in sequencing quality metrics or Tier I–II variant yield between specimen types.

Read PDF

Similar papers

Open access Oct 2026

Real-world plasma-based next-generation sequencing findings in metastatic lung adenocarcinoma: a single-center retrospective study

Plasma-based NGS identifies clinically relevant genomic alterations in metastatic lung adenocarcinoma and complementstissue-based molecular testing in routine practice in a real-world setting.

E. Kocaaslan, Emir Göçer, Fırat Akagündüz et al. · 0 citations
Open access Sep 2026

Optimizing DNA Extraction from Archival Prostate Biopsy Samples.

PURPOSE In this paper, we compare the performance of three distinct nucleic acid extraction protocols in a large population-based prostate cancer cohort, aiming to optimize DNA yield from limited tumor samples in prostate needle biopsies. MATERIAL AND METHODS We utilized two commercially available extraction kits and...

A. Amaral, Lia DePaula Oliveira, O. Dairo et al. · 0 citations
Nov 2026

Feasibility of Shallow Whole-Genome Sequencing-Based Circulating Tumour DNA Analysis in Canine Multicentric Lymphoma: A Pilot Study.

Lymphoma is a common canine malignancy with high morbidity and variable prognosis. Circulating tumour DNA (ctDNA) has emerged as a minimally invasive biomarker for tumour burden, treatment response and prognosis in human lymphoma. However, the feasibility of applying shallow whole-genome sequencing (sWGS)-based ctDNA a...

Gyuhyun Kim, Jinhee Jang, Se-Hoon Kim et al. · 0 citations
Open access Oct 2026

Validation of a ctDNA-Based comprehensive genomic profiling panel (IST80 Plus) for advanced non-small cell lung cancer

Circulating tumor DNA (ctDNA) profiling can complement tissue testing in advanced non-small-cell lung cancer (NSCLC), particularly when tissue is unavailable or unable to capture tumor heterogeneity. We evaluated the analytical and clinical performance of Illumina Solid Tumor Panel 80 (IST80 Plus), a focused hybrid-cap...

P. Mediavilla-Medel, R. Serna-Blasco, Lucía Robado de Lope et al. · 0 citations
Open access Nov 2026

Plasma cell-free DNA-based next-generation sequencing for molecular profiling of diffuse gliomas

Abstract Purpose To evaluate the utility of plasma-derived cell-free DNA (cfDNA) using targeted next-generation sequencing (NGS) for molecular profiling of diffuse gliomas (DG) by assessing concordance with matched tumor tissue DNA, mutation profiles, variant allele frequencies, therapeutically actionable alterations,...

Swati Singh, Jyotsna Singh, S. Bhardwaj et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.